[Evaluation of the treatment with thymopentin associated with radiotherapy in head and neck tumors].
The aims of the study has been the analysis of the optimal conditions for the use of thymopentin in reducing the incidence and severity of early and late complications following radiotherapy of patients with head and neck cancers submitted to radiotherapy by means of cobalt or linear accelerator. 168 patients of 10 Center have been examined. Analysis of the results demonstrated that the tymopentin reduce the incidence and severe reactions (p < 0.05) in statistically significant manner in cases of irradiation of the hypopharynx, oropharynx in oral cavity. The complications were more frequent during cobalt beam therapy (p < 0.01) and the beneficial effect of the immunomodulating treatment were greater for females than the males (p < 0.05).
Trinci
M
M
Istituto di Radiologia, Università degli Studi di Roma La Sapienza.
Belli
G
G
Santarelli
M
M
Raffetto
N
N
Trinci
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D016305:Thymopentin / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D016305:Thymopentin
Valutazione del trattamento con timopentina associato alla radioterapia nei tumori della testa e del collo.